A Phase 2 interventional study of D-2570 and Placebo in PsA (Psoriatic Arthritis), sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by InventisBio Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Psoriatic with a site in China — 10 open to participants now, 19 under way, 11 of them phase 3. Arthritis, Psoriatic · China.
Among the 34 studies in Arthritis, Psoriatic with a site in China, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 13 of the 18 other live ones, and was the 31st registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →10 of the 34 studies in Arthritis, Psoriatic with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Takeda · Sites in China, United States, Argentina and 17 more countries
Ages 18+
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Sites in China
Ages 18–75
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 15 more countries
Ages 3+
Hansoh BioMedical R&D Company · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 15 · Phase 4 2
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 222 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 208 across the 27 interventional studies, 400 across the 7 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 34 have an industry lead sponsor. The 10 most frequent:
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
InventisBio Co., Ltd has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Psoriatic with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957550Phase 3Jiangsu HengRui Medicine Co., Ltd.To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis | 2026-12-13 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
| NCT07321873Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | 2027-06-28 |
| NCT07406035Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 34 studies in Arthritis, Psoriatic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
The study is divided into three groups, each will include 74 subjects. The primary difference among the three groups lay in the dosage and whether they were placebo groups or not. In other aspects, such as population selection, randomization, blinding and outcome evaluation (safety and efficacy), are consistent among the three groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be randomized in a 1:1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2), or placebo (control arm). They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks. Subjects assigned to the placebo group (control arm) completed a 12-week control treatment period,they will then be randomized in a 1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2).They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
Drug: D-2570
Subjects will be randomized in a 1:1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2), or placebo (control arm). They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks. Subjects assigned to the placebo group (control arm) completed a 12-week control treatment period,they will then be randomized in a 1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2).They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
Drug: D-2570
Subjects will be randomized in a 1:1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2), or placebo (control arm). They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks. Subjects assigned to the placebo group (control arm) completed a 12-week control treatment period,they will then be randomized in a 1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2).They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
Drug: D-2570 · Drug: Placebo
Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.Subjects assigned to the placebo group (control arm) completed a 12-week control treatment period,they will then be randomized in a 1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2).They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.Subjects assigned to the placebo group (control arm) completed a 12-week control treatment period,they will then be randomized in a 1:1 ratio to D-2570 (experimental arm 1), D-2570 (experimental arm 2).They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
Proportion of subjects achieving ACR20 at Week 12 of treatment.
Definition of ACR20:The number of tender joints and swollen joints both decreased by at least 20% compared with the baseline.
Time frame: Week 12
Proportion of subjects achieving minimal disease activity at Week 12 of treatment;
Time frame: Week 12
Proportion of subjects achieving very low disease activity at Week 12 of treatment;
Time frame: Week 12
Plasma concentrations of D-2570
Time frame: 0-week 24
safety(AEs)
An Adverse Event (AE) is definedas any new untoward medicaloccurrence or worsening of a preexistingmedical condition in a clinicalinvestigation participant administeredstudy treatment and that does notnecessarily have a causal relationshipwith this treatment.
Time frame: 0-week 24
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570